Research Roundup


Debbie Rigby takes a look at the latest in research news

COPD and Osteoporosis: Associated Factors in Patients Treated with Inhaled Corticosteroids

Osteoporosis is one of the significant comorbidities in chronic obstructive pulmonary disease (COPD). This small study patients with COPD using inhaled corticosteroids, BMD was significantly low compared with the controls. Patients with osteoporosis and COPD had significantly lower BMI than people without osteoporosis. These findings suggest that pulmonary dysfunction and low BMI are associated with osteoporosis in patients with COPD.

International Journal of Chronic Obstructive Pulmonary Disease 2020;15:2441-8.

Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids

The findings from two population-based nested case-control studies suggest that exposure to oral or inhaled corticosteroids is an independent risk factor for bone health in patients with asthma. People receiving 9 or more OCS prescriptions had a 4.5-fold increased risk of osteoporosis and fragility fractures. Steroid administration at the lowest possible level to maintain asthma control is recommended.

Thorax 2020;0:1–9.

Regular use of proton pump inhibitors and risk of type 2 diabetes

Prospective analysis of more than 200,000 participants without diabetes indicates that regular PPIs use increases the risk of type 2 diabetes by 24% compared to non-users. The risk of diabetes increased with duration of PPI use. After one year of use the NNH with PPIs was 319 and 77 at 3 years. Use of H2 blockers was also associated with 14% increased risk. the authors suggest that changes to the gut microbiota may underlie the increased risk.

Gut 2020.

Medscape summary

Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

In patients with heart failure and a reduced ejection fraction, empagliflozin reduced the risk and total number of inpatient and outpatient worsening heart failure events, with benefits seen early after initiation of treatment and sustained for the duration of double-blind therapy.

Circulation, first published 21 October 2020.

Previous ‘We need to step up.’
Next Delays, perceptions of unfair policies form basis for complaints

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.